DIA Stock Analysis: DiaSorin S.p.A. | MI
Diagnostics & Research | MI, Italy | Market Cap: 3.455m EUR | 12M Return: -23% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 15.1M
Qual. Beats: 0
Rev. Trend: 0.1%
Qual. Beats: -1
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
DiaSorin S.p.A. is an Italian diagnostics company founded in 1968 and headquartered in Saluggia, Italy. It researches, manufactures, and distributes immunodiagnostic and molecular diagnostic test kits across Europe, North America, and other international markets. Its portfolio spans infectious diseases, gastrointestinal diseases, hepatitis and retroviruses, endocrinology, metabolic disorders, tumor markers, and oncology, with flagship automated analyzer platforms sold under the LIAISON XL and LIAISON XS brand names.
The company also sells molecular diagnostic kits such as the Simplexa congenital CMV direct kit, the LIAISON PLEX Respiratory Flex Assay, and the LIAISON PLEX Yeast Blood Culture Assay, and incorporates the xMAP multiplex technology platform within its in vitro diagnostics offering. Its customers are primarily hospital and reference clinical laboratories, and a large share of revenue is generated from the recurring sale of proprietary reagents and consumables that run on DiaSorin-installed instruments, a typical commercial model in the in vitro diagnostics industry. The business sits within the global in vitro diagnostics (IVD) market, where regulatory clearances (e.g., FDA, CE-IVD) and an installed base of automated immunoassay analyzers are central to competitive positioning.
- LIAISON XL and XS reagent sales drive recurring diagnostic revenue
- Luminex acquisition expands molecular diagnostics margins and assay portfolio
- IVDR EU regulation increases compliance costs and product certification timelines
| Net Income: 195.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA -0.50 > 1.0 |
| NWC/Revenue: 16.90% < 20% (prev 39.80%; Δ -22.91% < -1%) |
| CFO/TA 0.12 > 3% & CFO 342.8m > Net Income 195.4m |
| Net Debt (-103.8m) to EBITDA (409.5m): -0.25 < 3 |
| Current Ratio: 1.37 > 1.5 & < 3 |
| Outstanding Shares: last quarter (53.9m) vs 12m ago -0.92% < -2% |
| Gross Margin: 65.86% > 18% (prev 62.15%; Δ 3.71% > 0.5%) |
| Asset Turnover: 40.32% > 50% (prev 45.38%; Δ -5.05% > 0%) |
| Interest Coverage Ratio: 11.49 > 6 (EBIT TTM 281.2m / Interest Expense TTM 24.5m) |
| A: 0.07 (Total Current Assets 759.6m - Total Current Liabilities 555.5m) / Total Assets 2.87b |
| B: 0.03 (Retained Earnings 99.4m / Total Assets 2.87b) |
| C: 0.09 (EBIT TTM 281.2m / Avg Total Assets 3.00b) |
| D: 1.15 (Book Value of Equity 1.53b / Total Liabilities 1.34b) |
| Altman-Z'' = 2.42 = A |
| DSRI: 1.26 (Receivables 209.0m/195.4m, Revenue 1.21b/1.42b) |
| GMI: 0.94 (GM 62.15% / 65.86%) |
| AQI: 0.99 (AQ_t 0.65 / AQ_t-1 0.65) |
| SGI: 0.85 (Revenue 1.21b / 1.42b) |
| TATA: -0.05 (NI 195.4m - CFO 342.8m) / TA 2.87b) |
| Beneish M = -2.98 (Cap -4..+1) = A |
As of July 11, 2026, the stock is trading at EUR 68.82 with a total of 467,204 shares traded. Over the past week, the price has changed by -1.40%, over one month by -1.80%, over three months by +14.75% and over the past year by -23.02%.
Current recommended Stop Loss: 65.70 (which is 4.5% or 1.4 ATR below the current price).
DiaSorin S.p.A. has no consensus analysts rating.
P/E Trailing = 26.5399
P/E Forward = 21.7391
P/S = 2.9554
P/B = 2.308
P/EG = 1.6349
Revenue TTM = 1.21b EUR
EBIT TTM = 281.2m EUR
EBITDA TTM = 409.5m EUR
Long Term Debt = 472.1m EUR (from longTermDebt, last quarter)
Short Term Debt = 227.9m EUR (from shortLongTermDebt, last quarter)
Debt = 69.2m EUR (Leases only: 69.2m)
Net Debt = -103.8m EUR (calculated: Debt 69.2m - CCE 173.1m)
Enterprise Value = 3.35b EUR (3.46b + Debt 69.2m - CCE 173.1m)
Interest Coverage Ratio = 11.49 (Ebit TTM 281.2m / Interest Expense TTM 24.5m)
EV/FCF = 16.34x (Enterprise Value 3.35b / FCF TTM 205.1m)
FCF Yield = 6.12% (FCF TTM 205.1m / Enterprise Value 3.35b)
FCF Margin = 16.97% (FCF TTM 205.1m / Revenue TTM 1.21b)
Net Margin = 16.17% (Net Income TTM 195.4m / Revenue TTM 1.21b)
Gross Margin = 65.86% ((Revenue TTM 1.21b - Cost of Revenue TTM 412.6m) / Revenue TTM)
Gross Margin QoQ = 65.93% (prev 65.18%)
Tobins Q-Ratio = 1.17 (Enterprise Value 3.35b / Total Assets 2.87b)
Interest Expense / Debt = 35.35% (Interest Expense 24.5m / Debt 69.2m)
Taxrate = 23.97% (61.2m / 255.5m)
NOPAT = 213.8m (EBIT 281.2m * (1 - 23.97%))
Current Ratio = 1.37 (Total Current Assets 759.6m / Total Current Liabilities 555.5m)
Debt / Equity = 0.05 (Debt 69.2m / totalStockholderEquity, last quarter 1.53b)
Debt / EBITDA = -0.25 (Net Debt -103.8m / EBITDA 409.5m)
Debt / FCF = -0.51 (Net Debt -103.8m / FCF TTM 205.1m)
Total Stockholder Equity = 1.61b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.52% (Net Income 195.4m / Total Assets 2.87b)
RoE = 12.11% (Net Income TTM 195.4m / Total Stockholder Equity 1.61b)
RoCE = 13.48% (EBIT 281.2m / Capital Employed (Equity 1.61b + L.T.Debt 472.1m))
RoIC = 9.49% (NOPAT 213.8m / Invested Capital 2.25b)
WACC = 6.95% (E(3.46b)/V(3.52b) * Re(6.55%) + D(69.2m)/V(3.52b) * Rd(35.35%) * (1-Tc(0.24)))
Discount Rate = 6.55% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -29.55 | Cagr: -0.27%
[DCF] Terminal Value 73.24% ; FCFF base≈218.7m ; Y1≈193.2m ; Y5≈158.5m
[DCF] Fair Price = 53.41 (EV 2.54b - Net Debt -103.8m = Equity 2.64b / Shares 49.5m; r=8.35% [WACC [floored]]; 5y FCF grow -14.22% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.21 | # QB: 0
Revenue Correlation: 0.09 | Revenue CAGR: 0.01% | SUE: -4.0 | # QB: -1
EPS current Quarter (2026-09-30): EPS=0.92 | Chg30d=-8.15% | Revisions=+25% | Analysts=2
EPS current Year (2026-12-31): EPS=3.83 | Chg30d=-0.56% | Revisions=-10% | GrowthEPS=-9.6% | GrowthRev=+2.7%
EPS next Year (2027-12-31): EPS=4.30 | Chg30d=-1.10% | Revisions=-36% | GrowthEPS=+12.3% | GrowthRev=+6.5%
[Analyst] Revisions Ratio: -21% (up=6, down=10)